Dosage guide · 5 mg vial

CJC-1295 DAC Dosage Protocol

Modified GRF 1-29 with DAC · long-acting GHRH analogue

The reference schedule uses CJC-1295 DAC twice weekly: 300 mcg in weeks 1–2, then 500 mcg, 750 mcg and 1,000 mcg in successive steps. With 2 mL in a 5 mg vial, the concentration is 2.5 mg/mL, so the 300 mcg starting amount is 12 units (0.12 mL) on a U-100 syringe.

How oftenTwice weekly

Starting dose300 mcg

Start = units12 units

Mix2 mL BAC water

Reviewed 25 Oct 2026 · Education only, not medical advice

CJC-1295 DAC 5 mg vial

Not currently stocked by Peak Peptides Australia

No product photo — this strength isn't stocked by Peak

Dosage chart How to mix Supplies Calculator About CJC-1295 DAC References

01 · DOSAGE CHART

CJC-1295 DAC dosage chart

Gradual twice-weekly approach · 5 mg vial + 2 mL BAC water

BAC water added

Concentration2.5 mg/mL

1 unit (U-100)25 mcg= 0.01 mL

How oftenTwice weeklySubcutaneous injection

2 mL is the mix on the matching 5 mg reference protocol, giving 2.5 mg/mL and 25 mcg per U-100 unit.

CJC-1295 DAC dosage chart for a 5 mg vial mixed with 2 mL of bacteriostatic water
Week	Dose each time	Syringe units
Weeks 1–2Start	300 mcg	12 units0.12 mL
Weeks 3–4	500 mcg	20 units0.2 mL
Weeks 5–6	750 mcg	30 units0.3 mL
Weeks 7–12Maintenance	1 mg	40 units0.4 mL

Twice weekly · 3–4 days apart · subcutaneous injection

The reference schedule uses two injections per week, spaced 3–4 days apart.

The source describes an 8–12 week schedule; it mentions an optional extension to 16 weeks but gives no additional chart step.

Community-reported reference amounts — CJC-1295 DAC has no TGA-approved or clinically established public dose. Education only, not medical advice. Dose amounts adapted from CJC-1295 DAC 5 mg vial dosage protocol (PeptideDosages.com); units are recalculated for the vial and mix selected above.

02 · HOW TO MIX

Mixing a 5 mg vial with 2 mL of BAC water

Using a 1 mL (100-unit) insulin syringe, 2 full draws of bacteriostatic water gives 2.5 mg/mL.

1
Add the water slowly
Wipe both rubber stoppers with an alcohol swab and let them dry. Draw 2 mL of bacteriostatic water and let it run slowly down the inside of the vial wall — not straight onto the powder.
2
Swirl gently
Swirl or roll the vial gently until the powder has dissolved. Give it a few minutes to settle if needed.
3
Don't shake it
Shaking can damage the peptide and cause foaming. Gentle swirling only.
4
Check it's fully clear
Only use it once it is fully clear with no particles. Label the vial with the date and 2.5 mg/mL, then store it in the fridge at 2–8 °C.

Full illustrated reconstitution guide

03 · SUPPLIES NEEDED

What you'll need

Counts follow the dosage chart above at the highest amount in each step, using a 5 mg vial mixed with 2 mL.

Length of protocol

3CJC-1295 DAC 5 mg vials10.2 mg needed in total

191 mL insulin syringesU-100, 27–31G · one per draw + one per vial mixed

1BAC water 10 mL bottle6 mL used for mixing

38Alcohol swabsSkin + stopper, every time

Plus an approved sharps container. Syringes and swabs are sold by Australian pharmacies — Peak Peptides and Pure Performance supply the bacteriostatic water.

Peak Peptides Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPeak Peptides Australia

Pure Performance Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPure Performance Australia

04 · CALCULATOR

Check a different amount

Enter your vial, water and dose to see the matching syringe units.

Concentration Calculator

Labelled Vial Amount (mg)

Verified Final Liquid Volume2 mL

Amount to Evaluate (not a recommendation)

mcg

Concentration

2.50 mg/mL

(2500 mcg/mL)

Calculated Liquid Volume

0.120 mL

Equivalent U-100 volume scale position

12markings (not biological IU)

Illustration of a U-100 volume scale, not preparation or injection guidance

05 · PROTOCOL DETAILS

About CJC-1295 DAC

Protocol overview

Starting dose: 300 mcg twice weekly in weeks 1–2
How it increases: 500 mcg in weeks 3–4, 750 mcg in weeks 5–6, then 1,000 mcg in weeks 7–12
Frequency: Twice weekly
When to take it: Space injections 3–4 days apart and use a consistent schedule
Schedule length: 8–12 weeks in the reference protocol
Common mix: 2 mL bacteriostatic water → 2.5 mg/mL

Storage

Before mixing: Keep the unopened lyophilised vial dry, dark and at low temperature; minimise light exposure.
After mixing: Refrigerate at 2–8 °C, protect from light and do not freeze the solution.
Never: Avoid repeated freeze–thaw cycles or use a solution that is cloudy or contains particles.

How it works

CJC-1295 DAC is a synthetic analogue of growth hormone-releasing hormone. It is designed to activate the GHRH receptor on pituitary cells, which can increase growth hormone release and downstream IGF-1 signalling.

The DAC modification enables binding to serum albumin. In rat research, this albumin-bound form remained in circulation longer than the parent GHRH fragment; in healthy-adult research, CJC-1295 had an estimated half-life of 5.8–8.1 days.

Illustrated mechanism explainer

What the research shows

Two randomised, placebo-controlled ascending-dose investigations in healthy adults aged 21–61 lasted 28 and 49 days. After one subcutaneous dose, mean growth hormone increased 2- to 10-fold for at least 6 days and mean IGF-1 increased 1.5- to 3-fold for 9–11 days.
In those investigations, the estimated CJC-1295 half-life was 5.8–8.1 days; after multiple doses, mean IGF-1 remained above baseline for up to 28 days. No serious adverse reactions were reported in those short investigations.
A separate healthy-male study measured hormone patterns one week after a single 60 or 90 mcg/kg injection: trough growth hormone increased 7.5-fold, mean growth hormone 46%, and IGF-1 45%, while pulse frequency and magnitude were unchanged.
A 120-participant, 12-week CJC-1295 investigation in people with HIV-associated visceral obesity was terminated and has no posted results on ClinicalTrials.gov.
The TGA identifies CJC-1295 as an example of an unapproved peptide product. It has not been evaluated by the TGA for safety, quality or effectiveness and is not included in the ARTG.

Reported side effects

The healthy-adult investigations were short and reported no serious adverse reactions; they cannot establish long-term safety.
The FDA CJC-1295 presentation describes injection-site reactions as the most frequently reported events: temporary pain, swelling and induration, sometimes with local urticaria.
The same FDA presentation lists flu-like symptoms, headache, irritability, anxiety, nausea and hives among reported effects; it does not establish their frequency or long-term risk.
For unapproved injectable peptides, the TGA warns that sterility, contents, manufacturing quality and product labelling may be uncertain, creating contamination, infection and local-tissue risks separate from the molecule itself.

Important notes

CJC-1295 is listed by the TGA as an unapproved peptide product, meaning it is not included in the Australian Register of Therapeutic Goods and has not been assessed by the TGA for safety, quality or effectiveness.
Prohibited in sport at all times: WADA lists CJC-1295 among growth hormone-releasing hormone analogues under section S2.2.4.
CJC-1295 DAC and products labelled CJC-1295 No-DAC are not interchangeable; confirm the exact compound identity before applying any calculation.
There is no clinically established public dose. The chart reproduces a reference-site educational schedule rather than a TGA-approved dose.
Never use a mixed vial that is cloudy or has particles in it.

Injection basics

Use a new sterile 1 mL (100-unit) U-100 insulin syringe, 27–31G, every time — never reuse or share.
Wipe the vial stopper and the skin with an alcohol swab and let both dry first.
Inject under the skin (subcutaneously) of the abdomen, thigh or upper arm, and rotate sites.
Put used syringes straight into an approved sharps container — the NDSS lists Australian disposal options.

Guidance: World Health Organization · National Diabetes Services Scheme (NDSS)

06 · QUICK ANSWERS